Platelets: still a therapeutical target for haemostatic disorders. - Wikidata - awgldk - TriplyDB

Platelets: still a therapeutical target for haemostatic disorders.

Platelets: still a therapeutical target for haemostatic disorders.

http://www.wikidata.org/entity/Q34486685

about

Recent advancements in erythrocytes, platelets, and albumin as delivery systems Antiplatelet Therapy for Secondary Prevention of Vascular Disease Complications.

P2860

Q26747764-06DC4604-FBE5-4C1E-B079-5DCE6D040BDB Q47657861-CB751884-5E74-4105-AB0A-AC1E7F1DFD1A

P2860

Platelets: still a therapeutical target for haemostatic disorders.

http://www.wikidata.org/entity/Q34486685

description

2014 nî lūn-bûn

@nan

2014 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年学术文章

@wuu

2014年学术文章

@zh-cn

2014年学术文章

@zh-hans

2014年学术文章

@zh-my

2014年学术文章

@zh-sg

2014年學術文章

@yue

name

Platelets: still a therapeutical target for haemostatic disorders.

@ast

Platelets: still a therapeutical target for haemostatic disorders.

@en

Platelets: still a therapeutical target for haemostatic disorders.

@nl

type

label

Platelets: still a therapeutical target for haemostatic disorders.

@ast

Platelets: still a therapeutical target for haemostatic disorders.

@en

Platelets: still a therapeutical target for haemostatic disorders.

@nl

prefLabel

Platelets: still a therapeutical target for haemostatic disorders.

@ast

Platelets: still a therapeutical target for haemostatic disorders.

@en

Platelets: still a therapeutical target for haemostatic disorders.

@nl

P1433

Q34486685-2E72DF24-B3E3-4EF8-B670-E674C29DA4C8

P1476

Q34486685-63AAC16F-8F9E-4BDB-AA77-10B22272E7A7

P2093

Q34486685-54F93198-07D9-48E0-B6DC-D10CA705343B

Q34486685-5F66B4D8-7FD3-43F5-8B70-AA30FC677A95

Q34486685-C72D5E0E-2D7F-46A7-B545-E6D56BC8440A

Q34486685-D764E8D6-119F-408F-9EFB-A7D92309D27E

Q34486685-E854E0E6-8B4D-4A4B-87D2-8A3244088513

P275

Q34486685-333E6D1A-CF9B-49C7-BDF8-5472BBD84273

P2860

Q34486685-0AD737B6-3E7F-429B-B3A8-95E24EC5145F

Q34486685-0DF9AAE4-A506-44BC-88DD-7C68BE054084

Q34486685-10247340-7600-418A-9000-67F340A26132

Q34486685-1052C2CD-2D1F-46C7-9E2A-44B82B7001A2

Q34486685-168D084F-7219-43ED-8B56-3B09401B183F

Q34486685-207173A4-A376-4811-93D9-EA0845B25C35

Q34486685-23447751-B345-4B56-B9CA-B624908CACCE

Q34486685-23691034-30DD-41E9-AE41-8CDF382E9AE2

Q34486685-2472C49B-6F2E-41A4-85FA-D9BA06DA4FCC

Q34486685-253D7170-2160-4306-8E07-F4817F7C9F7F

P304

Q34486685-8CCDE6F7-29C1-4F8C-8E0E-36CC4600AAD0

P31

Q34486685-EA24DD7D-B2A7-4503-8CDC-E807A39EDD8B

Q34486685-EDBD89F6-4292-46A3-9E81-E221A7493A88

P356

Q34486685-7DAED305-330F-4471-A4A0-40D213A73788

P407

Q34486685-79D643F3-DBFC-4A54-ADF7-4ED00B46F52E

P433

Q34486685-DB4F98F1-A3B3-456B-ABBE-91DF87E2F1AB

P478

Q34486685-4D110DDA-6A31-4F63-95F9-526F8FF5BBE0

P50

Q34486685-3B24D129-DE49-4020-94BC-508FEE7AC6F2

Q34486685-AB3A0C2F-E8C8-4F31-A266-F7DC926F6B4E

P5008

Q34486685-0E55D460-DB74-4D53-8BCA-66F9A7E919D3

P577

Q34486685-D6FC986D-F827-46F3-B076-58B1FA5021FE

P5875

Q34486685-253B51AD-7FAB-44F2-B6D1-0EFAFA5C36E9

P698

Q34486685-239EA6AE-A49A-43D6-8A6F-F777E5DF9BB8

P921

Q34486685-3C64D6AA-3CF7-4729-9108-D0B87A48A32B

Q34486685-4B729A10-826C-4D66-A35E-192DDC7FB0C9

Q34486685-5EA61B0F-5999-4869-8521-BAA2535257B9

P932

Q34486685-8C708EF2-F049-473B-B65B-749AEA5263A9

P356

P1433

International Journal of Molecular Sciences

P1476

Platelets: still a therapeutical target for haemostatic disorders.

@en

P2093

André Luiz Lourenço

http://www.w3.org/2001/XMLSchema#string

Lucio M Cabral

http://www.w3.org/2001/XMLSchema#string

Max Seidy Saito

http://www.w3.org/2001/XMLSchema#string

Pabulo Henrique Rampelotto

http://www.w3.org/2001/XMLSchema#string

Reinaldo Barros Geraldo

http://www.w3.org/2001/XMLSchema#string

P275

Creative Commons Attribution

P2860

Maternal and foetal outcomes following natural vaginal versus caesarean section (c-section) delivery in women with bleeding disorders and carriers

Maternal and foetal outcomes following natural vaginal versus caesarean section (c-section) delivery in carriers and women with bleeding disorders

The antithrombotic profile of aspirin. Aspirin resistance, or simply failure?

Platelet function tests: a review of progresses in clinical application

Controversies in antiplatelet therapy for patients with cardiovascular disease

Blood platelet reactivity and its pharmacological modulation in (people with) diabetes mellitus

Aspirin resistance: moving forward with multiple definitions, different assays, and a clinical imperative

Cyclooxygenase inhibitors and the antiplatelet effects of aspirin

Preventing atherosclerotic events with aspirin

Aspirin for the primary prevention of cardiovascular events: a summary of the evidence for the U.S. Preventive Services Task Force

P304

17901-17919

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3390/IJMS151017901

http://www.w3.org/2001/XMLSchema#string

P407

P433

10

http://www.w3.org/2001/XMLSchema#string

P478

15

http://www.w3.org/2001/XMLSchema#string

P50

Helena C Castro

Plínio Cunha Sathler

P5008

P577

2014-10-07T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

266613839

http://www.w3.org/2001/XMLSchema#string

P698

25295482

http://www.w3.org/2001/XMLSchema#string

P921

vascular hemostatic disease

hemic and immune systems

P932

4227196

http://www.w3.org/2001/XMLSchema#string